AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer
September 09, 2019 at 03:38 AM EDT
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs.